Navigation Links
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Date:1/3/2008

ROCKVILLE, Md., Jan. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its aurora kinase/angiogenesis inhibitor, ENMD-2076.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a novel, dual-acting, kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular effects.

Carolyn F. Sidor, MD, MBA, EntreMed Vice President and Chief Medical Officer commented on the IND, "Acceptance of the Investigational New Drug application for ENMD-2076 initiates the clinical program for our first compound that targets kinases. This is an exciting class of compounds with several recently approved in oncology indications. ENMD-2076 is unique in class because it not only inhibits Aurora A selectively over Aurora B, it also inhibits a number of other kinases important in the growth of tumors and, in particular, growth factor receptors critical to angiogenesis. ENMD-2076 has potent antitumor activity
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... 14, 2014 Holloway America today announced ... material test reports (MTRs) for all pressure vessels and ... results is particularly important for equipment that must meet ... Library features search functionality that allows authorized users to ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... 6, 2011 Spinal muscular atrophy (SMA) is the leading ... treatment other than supportive care. In the Proceedings of ... June 6), researchers at Children,s Hospital Boston show how loss ... and weakness, and suggest a promising approach to treating the ...
... 6, 2011 Oxford BioMedicaplc ("Oxford BioMedica" ... company, today announces that it has signed a research ... specialising in the development of engineered antibody fragments for ... in vivo diagnostic imaging agent using an ...
... Ganeden Biotech announced the sale of ... brands of probiotic dietary supplements to Schiff ...  Ganeden will also receive royalties on Schiff products containing ... rights to use Ganeden,s probiotic technology, GanedenBC30™, in the ...
Cached Biology Technology:New Approaches Open up in Spinal Muscular Atrophy 2New Approaches Open up in Spinal Muscular Atrophy 3Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb 2Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb 3Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 3
(Date:4/23/2014)... of Exeter researcher has shed light on how an ... Australia,s remote outback have become reviled as pests and ... the Environment and Sustainability Institute at the University of ... in Australia, from their historic role helping to create ... unwelcome "invader." , The deserts of the Australian outback ...
(Date:4/23/2014)... social mammals, ravens form different types of social relationships ... they also form strict dominance relations. From a cognitive ... key ability in daily social life ("knowing who is ... members have with each other sets the stage for ... of this study have been published in the scientific ...
(Date:4/23/2014)... a 2 million Food Standards Agency (FSA) project to ... industry workers. , Norovirus outbreaks can rapidly affect ... of frozen strawberries infected 11,000 people in Germany, but ... which strains cause infection and which foods are the ... Researchers will produce data that will help the FSA ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Ravens understand the relations among others 2
... available in German . , A new ... could help to understand the positive effect of dietary restriction ... and mice) have shown that dietary restriction increases longevity, but ... the female fruit fly reproduces less frequently with a reduced ...
... discovery is challenging accepted thinking about amyloids the fibrous ... and may open up a potential new area for ... structures made up of proteins sometimes known as fibres - ... their formation which can damage cells and cause disease. ...
... Hausen and his co-workers discovered that specific types of human ... these pathogens cause cells to degenerate. It is known today ... Both proteins switch off different cellular control functions, thus promoting ... co-workers at DKFZ have now discovered another mechanism by which ...
Cached Biology News:How nutrition affects healthy aging 2New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2
... the Quansys Biosciences Q-Plex Array is a ... for human, mouse, and rat research. The ... quantitative ELISA-based test where 4 distinct capture ... of a 96-well plate in a defined ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... kit for 10 chips provides the chips ... with the Experion automated electrophoresis system. This ... x 520 microliters Pro260 gel, 45 microliters ... kD), 400 microliters Pro260 sample buffer, and ...
... The expertise that made the original Gene ... electroporation system available has been applied in the ... circuitry. The modular design of the Gene Pulser ... the accessory that has the widest range of ...
Biology Products: